

KRCA-0008

Catalog No: tcsc3341



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1472795-20-2

Formula:

$C_{30}H_{37}ClN_8O_4$

Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:

Ack1;ALK

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

609.12

Product Description

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like


properties without hERG liability.

IC50 value: 12 nM/4 nM(ALK/Ack1) [1]

Target: ALK/Ack1 inhibitor

KRCA-0008 retains good drug-like properties: good water-solubility (54 μ M in 5% DMSO-water, 150 μ M in 5% DMSO-PBS buffer) with moderate plasma protein binding (93% in rat) and low brain exposure (C_{brain}/C_{plasma} = 0.02). It has good liver microsomal stability (% remaining after 30 min: 52% in mouse, 89% in rat, 72% in human) and little to no CYP inhibition (1A2, 2C9, 2D6, 3A4 @ 10 μ M). It does not appear to cause hERG blockade (patch clamp IC₅₀ = 30 μ M) and is negative on Ames test (1000 μ g/plate), chromosomal aberration assay and micronucleus assay.

KRCA-0008 also shows promising pharmacokinetic parameters in both mice and rat (oral bioavailability = 66-94.5%). KRCA-0008 shows a modest tumor growth inhibition in vivo activity in H3122 human lung cancer bearing mice model comparable to Crizotinib without significant body weight change. It is important to mention the KRCA-0008 25 mpk and 50 mpk groups did not show dose-dependent tumor growth inhibition.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!